{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-073929","form_type":"8-K","ticker":"OGN","cik":"0001821825","company_name":"Organon & Co.","filed_at":"2025-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.141789+00:00","generated_at":"2026-05-17T20:56:18.575953+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.72,"calibrated_materiality_score":0.72,"confidence":"high","headline":"Organon Q2 revenue $1.594B, adj. EPS $1.00; raises FY revenue guidance to $6.275-6.375B","bullets":["Revenue $1.594B, down 1% YoY; GAAP net income $145M ($0.56 EPS); non-GAAP adj. EPS $1.00, down 11% YoY.","Adjusted EBITDA $522M (32.7% margin) vs $513M (31.9%) prior year; repaid $345M of long-term debt in Q2.","Women's Health revenue up 2% ex-FX; fertility business +15% ex-FX; Nexplanon flat ex-FX.","Biosimilars up 6% ex-FX (Hadlima growth); Established Brands down 4% ex-FX on Atozet LOE in Europe.","FY 2025 revenue guidance raised to $6.275-6.375B; adj. EBITDA margin guidance affirmed at 31-32%."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-073929","json":"https://secwatch.observer/filing/0001104659-25-073929.json","markdown":"https://secwatch.observer/filing/0001104659-25-073929.md","text":"https://secwatch.observer/filing/0001104659-25-073929.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1821825/000110465925073929/0001104659-25-073929-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1821825/000110465925073929/tm2522571d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T20:56:18.575953+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}